References
- McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–824.
- Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–1301.
- Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe français du myélome. N Engl J Med. 1996;335(2):91–97.
- Abidi MH, Agarwal R, Tageja N, et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant. 2013;19(1):56–61.
- Bensinger WI, Becker PS, Gooley TA, et al. A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2016;51(1):67–71.
- Hari P, Reece DE, Randhawa J, et al. Final outcomes of escalated melphalan 280 mg/m(2) with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019;54(2):293–299.
- Veeraputhiran M, Jain T, Deol A, et al. BEAM conditioning regimen has higher toxicity compared with High-Dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2015;15(9):531–535.
- Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol. 2005;130(4):588–594.
- Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004;100(12):2607–2612.
- Benson DM, Jr., Elder PJ, Lin TS, et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res. 2007;31(8):1069–1075.
- Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. Cancers (Basel). 2021;13(4):863.
- Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the intergroupe francophone du myélome 9502 randomized trial. Blood. 2002;99(3):731–735.
- Annamaria Brioli M, Felix V H, Mügge L-O, et al. Full dose or reduced dose melphalan for autologous stem cell transplantation in multiple myeloma: a single center analysis on 187 consecutive patients. Blood. 2018;132(Supplement 1):4625–4625. MD MD MDMDPhD MD MD MD
- Srour SA, Milton DR, Bashir Q, et al. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021;106(12):3211–3214.
- Auner HW, Iacobelli S, Sbianchi G, et al. Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party. Haematologica. 2018;103(3):514–521.
- Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431–e442.
- Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–147.
- Straka C, Schaefer-Eckart K, Hertenstein B, et al. Long-term outcome of a prospective randomized trial comparing continuous lenalidomide/dexamethasone with lenalidomide/dexamethasone induction, MEL140 with autologous blood stem cell transplantation and single agent lenalidomide maintenance in patients of age 60-75 years with newly diagnosed myeloma. Blood. 2022;140(Supplement 1):287–288.